Genetic association studies investigating the role of the +118A allele of the human -opioid receptor gene in risk for alcohol dependency have produced inconsistent findings, possibly because of the failure to recognize sampling methodology difficulties inherent in association studies of polygenic disorders. We examined the frequency of the AA genotype and A allele in several groups of substance-dependent cases, unrestricted controls, and super controls screened for the use of alcohol and cigarettes. Our findings and analyses suggest that the OPRM1 +118 polymorphism is a general risk gene for substance dependence, but is not specific to a particular substance. The nature of the conferred risk is likely to be in use of multiple substances, but it is not yet determined if the risk could be expressed in severity of use of any particular substance. The contribution of the gene to risk for substance dependence is small, and is detected most easily in studies that use control samples that are screened for all forms of substance dependence.
Introduction
Evidence from epidemiologic, family, and genetic studies to date suggest that the entire class of substance abuse disorders falls into the category of complex polygenic disorders. Data from the National Comorbidity Study 1 reveal that the diagnosis of alcoholism is associated with increased risk not only for psychiatric disorders, but also for all other forms of drug dependence with odds ratios that range from 9.8 for men to 15.8 for women. A recent family study 2 has shown that predominant use of a single drug (alcohol, opiate, cocaine, marijuana) in a proband is associated with increased predominant use in family members not only of the proband drug, but also of other drugs. This effect was found to hold even when controlling for the presence of antisocial personality disorder and the use of alcohol, the most commonly abused drug. A study examining drug use among relatives of proband alcoholics 3 found that approximately 50% of brothers and 25% of sisters carried a lifetime diagnosis of alcohol dependence. Additionally, however, sibs of alcoholic probands were also at substantially increased risk for marijuana dependence, cocaine dependence, and heavy smoking even after controlling for alcohol dependence in the siblings.
Twin studies not only reveal large (ie, Ն50%) genetic components to risk for disorders such as alcohol dependence 4 and cigarette smoking, 5 but have also shown that a substantial portion of the genetic risk for substance dependence disorders is shared in common. A recent study, 6 employing the Vietnam Era Twin Registry, reported that 25.5% of the genetic risk for DSM-IIIR diagnosed alcohol and nicotine dependence was common to both disorders.
The search for candidate risk genes in substance abuse has focused primarily on alcohol dependence, and this endeavor has underscored the methodological difficulties in association studies of polygenic disorders. Numerous studies of the dopamine D2 receptor gene (DRD2), for example, have produced contradictory results, possibly because of case and control sampling procedures that failed to consider the severity of alcohol use and the conjoint use of other substances, including illegal drugs and especially cigarettes.
Because the endogenous opioid system plays a role in the reinforcing effects of a number of other drugs, we 7 previously investigated a functional coding polymorphism (+118A/G) within the reward-associatedopioid receptor gene (OPRM1) as a risk candidate for alcoholism in samples that were largely Caucasian. Our results supported the AA genotype and A allele as risk factors for alcoholism, with an odds ratio (OR) of 2.10 (Confidence Interval = 1.11-3.98) by genotype. Because we did not control for use of other substances in our alcoholics and controls and assumed that OPRM1 +118-other drug associations would be equivalent in the two groups, we proposed that our findings suggested that the risk conferred by this polymorphism was specific to alcoholism. Other recent studies have provided results that question this straightforward conclusion in Caucasian populations.
Bergen and colleagues 8 also investigated a possible association between the OPRM1 +118 polymorphism and alcoholism in both US and Finnish Caucasians. They reported a lack of association in both groups. However, the frequency of the AA genotype was 20% greater in the US alcoholics (95%) than in US controls (75%). Notably, 75% of their alcoholic group also reported illegal drug use and the control group was screened for diagnosed substance abuse, but not restricted for amount or type of social drug use. Examination of the Bergen et al data tables reveals that power for the US Caucasian samples was somewhat limited (power = 0.60). Sander et al 9 reported a study in which the OPRM1 +118A allele and AA genotypes were slightly more frequent in a sample of German controls than in alcoholics who had been screened to exclude patients with other substance abuse or psychiatric disorder. Controls were randomly selected from anonymous blood donors, however, and thus likely included regular substance users or abusers. Gelernter et al 10 found no difference in frequencies for the OPRM1 +118A/G genotype among Caucasian controls, drug-dependent, and alcohol-dependent samples. Again, controls were screened for psychiatric disorder, but not for regular use or abuse of alcohol or drugs.
In this study we expanded the sampling methodology of our previous work to examine the frequencies of the AA genotype and A allele in various groups of alcoholics and controls defined by severity and type of use of other substances. Because OPRM1 risk allele frequencies are likely to differ among populations defined by ethnic and possibly other characteristics, 10, 11 we limited our investigation to Caucasian samples.
Methods

Subjects
The patient sample consisted of 179 Caucasians who were unrelated individuals recruited from the substance abuse treatment program of a large, metropolitan VA medical center. All cases met the criteria for alcohol dependency as defined by DSM-IV and reported alcohol as the primary drug of dependency. Data from 80 of these cases were reported in our previous study. 7 Detailed information about history of substance use was obtained by means of a structured interview administered by trained graduate-level research assistants. The mean age of the alcoholic sample was 46.9 ± 8.6 years and all but four cases were males. Three subsamples were also selected from this patient group on the basis of structured interviews of substance abuse history. These included: (a) the ETOH-NIC-DRUG group, 43 cases with a history of abuse of other substances (primarily cocaine and marijuana) and current daily use of cigarettes (27.9 ± 10.1 cigarettes per day); (b) the ETOH-NIC group, 91 cases with no history of abuse of other illegal substances who were current smokers (30.3 ± 14.8 cigarettes per day); and (c) ETOH ONLY group, 17 cases with no history of use of illegal substances or daily use of cigarettes.
The control sample consisted of 297 Caucasians (48.1% male) who were selected as part of a larger epidemiologic study of healthy elderly residing on the west coast of Florida 12 and had not been participants in any of our previous studies. Information regarding history and current use of alcohol and cigarettes was Molecular Psychiatry obtained as part of an extensive structured evaluation conducted by trained interviewers, as described in detail by Small et al. 12 All cases in this sample were over the age of 60 (mean age = 72.8 ± 6.1), thus guaranteeing exposure to risk for alcohol abuse and nicotine dependence. The sample was characterized by individuals with varying histories of use of alcohol and cigarettes. A group of 63 individuals, all of whom had a lifetime history of less than one alcoholic drink per month and less than one cigarette per week, was selected from the larger unrestricted control sample to serve as a super control sample.
Genotyping DNA was extracted from peripheral blood samples with the Puregene kit (Gentra Systems, Minneapolis, MN, USA) or by using standard phenol-chloroform methods. The OPRM1 +118A/G restriction fragment length polymorphism (RFLP) was amplified using primers and conditions described previously. 8 An A → G substitution in the 95-bp PCR fragment (predicting an Asn-to-Asp amino acid substitution at position 40 of the receptor protein) creates a DrdI recognition sequence, which, when digested, results in 22-bp and 73-bp fragments.
Statistical analysis
The 2 statistic was used to compare genotype and allelic distributions among control and case samples and subsamples, as well as with data reported in previous studies. In this, as well as in previous studies, the GG genotype was rare in both case and control samples. Analyses for genotypes were therefore conducted on the AA homozygous genotype vs the G-carrying genotypes (AG and GG). ORs and corresponding 95% confidence intervals (CIs) were calculated according to standard methods. Power analyses were conducted for each 2 analysis, with alpha set at 0.05 for a twotailed test. For analyses of genotypes, power to detect a 15% rate difference in cases and controls was estimated. For analyses of allele frequencies, power to detect a 10% rate difference was estimated. Statistical analyses were performed using SPSS for Windows release 8.0.2. Power analyses were carried out using Power and Precision release 1.0.
Four planned 2 analyses were the focus of the study. These were the comparisons of genotype and allele frequencies between the total alcoholic sample and the unrestricted control sample and a parallel set of comparisons between the total alcoholic sample and the super control sample. Other 2 analyses were conducted on study subgroups and data from previous studies to explore methodological issues and to provide more detailed comparisons with other studies based on case and control group characteristics. To allow comparisons with previous studies, significance levels were not adjusted for the number of statistical tests conducted overall.
Results
Preliminary analyses using the 2 statistic showed the OPRM1 genotype distributions in case (P = 0.56) and control (P = 0.69) samples to be in Hardy-Weinberg equilibrium. There was no relationship between gender and OPRM1 genotype in the full control sample (P = 0.36) and subsequent analyses were therefore not conducted separately by gender. Using the unrestricted control sample as a reference group, the entire group of alcoholics was found to have a significantly higher frequency of the AA genotype ( 2 = 7.69, P = 0.006) and the AA allele ( 2 = 8.25, P = 0.004), with approximately a two-fold increase in risk for cases with the AA genotype. Analysis of alcoholic subsamples, however, revealed that only the ETOH + NIC + DRUG group had a significantly higher frequency of the AA genotype ( 2 = 7.50, Ps = 0.006). No case subsample had a significantly higher A allele frequency than unscreened controls.
A more revealing pattern of results, however, appears when using the super controls as a reference group. In analyses of genotypes, the entire group of alcoholics as well as all but the ETOH ONLY subsample have significantly higher frequencies of the AA genotype (Ps Ͻ 0.04), with ORs ranging from 2.18 to 6.67. Although the ETOH ONLY group had approximately a 10% increase in AA genotype frequency in comparison to super controls, significant results were not found, possibly because of especially low power for the analysis (0.24). Parallel results were obtained for the analyses of the allele frequencies.
Examination of the genotype and allele frequencies among the alcoholic subsamples reveals no significant findings, although power for these analyses is low, exceeding 0.70 in only one instance. There is a trend (P Ͻ 0.10) for the ETOH + NIC + DRUG group to have higher frequencies of the AA genotype and A allele than the other alcoholic subsamples. Table 1 also presents genotype and allele frequencies for alcoholics and drug-dependent cases derived from tables presented in three previous studies examining the OPRM1 +118 polymorphism in Caucasians, each of which failed to confirm a relationship between the polymorphism and alcoholism. Notably, two of these studies provide case genotype and allele frequencies similar to those of our alcoholic subsamples. The alcoholics without other illegal drug use described in the Sander et al 9 study have a similar frequency of the AA genotype (79.8%) and A allele (89.3%) as do the ETOH ONLY and ETOH + NIC subsamples. The alcoholics described by Bergen et al 8 were also largely (75%) illegal drug users and have a frequency of the AA genotype (95.0%) and A allele (97.5%) similar to our ETOH + NIC + DRUG subsample. The A allele frequencies reported by Gelernter et al 10 for separate samples of primary alcoholics and primary drugdependent cases, however, are lower than those in any of our alcoholic subsamples.
Using the super control group as a reference group, the case samples of both the Sander et al and the Bergen et al studies were found to have a significantly higher frequency of the AA genotype ( 2 = 12.17, P = 0.001 and 2 = 23.12, P = 0.001, respectively). Analyses of the A allele frequencies yielded parallel findings (Ps Ͻ 0.02). Analyses for the Gelernter et al samples, however, produced insignificant findings, despite adequate power.
Discussion
Consistent with our previous findings, we find that the OPRM1 + 118A allele is significantly associated with increased risk for alcohol dependency, when comparing an otherwise undefined sample of alcoholics to a sample of nonalcoholic but otherwise unrestricted controls. Examination of the pattern of genotype and allele frequencies among subgroups of the alcoholic and control samples, however, provides a more comprehensive perspective on association study methodology and the Molecular Psychiatry contribution of the OPRM1 + 118 polymorphism to risk of substance dependence.
Concerns about the composition of control samples in case association studies of candidate risk genes for alcoholism and substance dependence have been previously voiced. 13, 14 For complex polygenic disorders the frequency of a specific risk allele may increase in groups with greater severity of the disorder. Thus, even mild use of alcohol or use of other addictive substances such as nicotine may inflate risk allele rates in control samples and serve to minimize frequency differences between cases and controls. In support of this possibility, we obtained significant findings in analyses using both unscreened and super control groups, but with ORs that were approximately 50% higher when using super controls as the reference group for statistical analyses.
In contrast to the interpretation suggested by our previous study, the pattern of results raises an alternative possibility that OPRM1 may function as a general risk gene for substance abuse rather than a specific risk gene for alcoholism. The strongest argument for this alternative is the fact that there is a consistent and orderly trend for higher frequencies of the AA genotype and A allele in groups with increasing numbers of substances used. Using the super control group as a reference, ORs increase from 1.63 for alcoholics with no history of daily smoking or illegal substance abuse to 6.67 for those with a history of both. Specific analyses that tested differences in genotype and allele frequencies among the alcoholic groups did not reach significance, possibly because sample sizes were small and power was estimated at being less than 0.50 for the comparisons of interest (see Table 1 ). A definitive test of the relationship between OPRM1 and substance dependence, however, will require investigation of substance cases who are dependent on substances other than alcohol and nicotine. Elevated frequencies of the AA genotype and A allele in groups of cocaine or opioid dependent samples, together with the data reported here, would provide strong evidence for OPRM1 as a general risk gene for substance dependence.
Our results potentially provide a background for interpretation of the results of prior studies. Although reporting insignificant results, both the Bergen et al and Sander et al alcoholic samples have significantly higher AA genotype and A allele frequencies than our group of super controls. The failure of these studies to detect significant differences may have been due to their use of unscreened controls. Similar analyses for the case samples used by Gelernter et al did not produce significant results. Notably, the Gelernter et al samples have lower A allele rates (86.5%) than comparable groups described by us (ETOH + NIC + DRUG, 96.5%) or Bergen et al (97.5%).
We note that our focus on Caucasian samples is not complete protection against spurious findings due to ethnic stratification, even in view of the fact that our samples were obtained within a relatively restricted geographic locale. While protecting against more obvi-ous risk of stratification error, spurious associations between markers and phenotypes can occur as a result of differences in Caucasian ethnic stratification between case and control samples. 15 Efficient methods of testing for these differences are in development 15, 16 and will allow future studies to protect against errors of this type.
Our findings provide support, but not conclusive evidence, that the OPRM1 + 118 polymorphism is a general risk locus for substance dependence and is not specific to a particular substance. The nature of the conferred risk is likely to be in use of multiple substances, but it is not yet determined if the risk could be expressed in severity of use of any particular substance. The contribution of the gene to risk for substance dependence is small, and is detected most easily in studies that use control samples that are screened for all forms of substance dependence.
